H.C. Wainwright says the HARMONi-2 OS interim data was not powered for statistical significance. It keeps a Buy rating on Summit Therapeutics (SMMT) with a $44 price target The market seemed to have “heavily overreacted” on Friday, the analyst tells investors in a research note. The firm views the approval in China as a risk-mitigating factor for ivonescimab’s utility and potential approval in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
- BMO says Keytruda ‘still reigns’ after ivonescimab survival data
- Citi says buy Summit amid ‘significant market confusion’
- Summit Therapeutics down 32% after resuming trading
- Summit Therapeutics trading resumes